Published in Bone Marrow Transplant on September 01, 1994
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia (2007) 3.95
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol (1998) 3.21
The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol (1999) 2.40
Mantle cell lymphoma-- an entity comes of age. Blood (1996) 2.30
Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol (2002) 2.28
Current concepts in anticoagulant therapy. Mayo Clin Proc (1995) 2.21
Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet (1993) 2.12
Defining the risks of subclavian-vein catheterization. N Engl J Med (1994) 2.08
Paroxysmal nocturnal hemoglobinuria as a marker for clonal myelopathy. Am J Med (1992) 2.04
Low protein S in essential thrombocythemia with thrombosis. Am J Hematol (1989) 2.03
Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. J Clin Oncol (1993) 2.00
High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med (1987) 1.98
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol (1991) 1.94
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res (2000) 1.81
International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol (1999) 1.76
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol (1997) 1.75
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood (2001) 1.74
Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. J Clin Oncol (1993) 1.69
Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol (1985) 1.67
Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol (1993) 1.66
Quantitative plasma D-dimer levels among patients undergoing pulmonary angiography for suspected pulmonary embolism. JAMA (1993) 1.64
Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med (1989) 1.62
Plasma D-dimer: a useful tool for evaluating suspected pulmonary embolus. J Nucl Med (1993) 1.59
High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol (1993) 1.58
Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings. Blood (1987) 1.56
F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma (2007) 1.54
Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol (1996) 1.53
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia (2005) 1.51
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 1.49
Clinical applications of hematopoietic growth factors. J Clin Oncol (1995) 1.47
Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models. Lab Anim (2011) 1.43
Effects of simvastatin only or in combination with continuous combined hormone replacement therapy on serum lipid levels in hypercholesterolaemic post-menopausal women. Eur Heart J (2000) 1.41
Correlation of myocardial fractional flow reserve with thallium-201 SPECT imaging in intermediate-severity coronary artery lesions. J Invasive Cardiol (2000) 1.41
Allogeneic bone marrow transplantation: problems and prospects. Mayo Clin Proc (1992) 1.39
Measurement of myocardial fractional flow reserve during coronary angioplasty in infarct-related and non-infarct related coronary artery lesions. J Invasive Cardiol (2000) 1.39
Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma. Leuk Lymphoma (1998) 1.39
Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol (1990) 1.37
Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood (1992) 1.36
Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2007) 1.34
Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol (2001) 1.34
Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant (2001) 1.31
Allogeneic bone marrow transplantation for low-grade lymphoma. Blood (1998) 1.29
Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst (2001) 1.26
Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol (2000) 1.26
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant (2004) 1.26
Splenic rupture in patients with hematologic malignancies. Cancer (1981) 1.22
Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol (1996) 1.22
The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood (1991) 1.20
Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol (2001) 1.20
Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant (2008) 1.19
Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia (2003) 1.18
Remission of giant lymph node hyperplasia with anemia after radiotherapy. Cancer (1979) 1.16
Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant (2001) 1.16
Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant (2006) 1.15
Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol (1999) 1.13
The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol (1988) 1.11
Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost (1998) 1.10
The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia (2004) 1.10
Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant (1998) 1.10
Infrastructure development for human cell therapy translation. Clin Pharmacol Ther (2007) 1.10
Towards understanding the peripheral T-cell lymphomas. Ann Oncol (2004) 1.09
Monoclonal antibodies marking T lymphocytes in paraffin-embedded tissue. Am J Pathol (1987) 1.09
High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood (1989) 1.09
The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol (2002) 1.09
High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol (1997) 1.07
Hematopoietic growth factors. CA Cancer J Clin (1996) 1.07
Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant (2000) 1.06
Typhlitis in acute leukemia: successful treatment by early surgical intervention. Cancer (1979) 1.05
Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol (1999) 1.05
Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant (2004) 1.05
Mayo Clinic experience with allogeneic and syngeneic bone marrow transplantation, 1982 through 1990. Mayo Clin Proc (1992) 1.05
Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc (1984) 1.05
Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol (1989) 1.04
Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant (2001) 1.04
Cytogenetic and molecular detection of residual leukemic cells after allogeneic bone marrow transplantation in chronic granulocytic leukemia. Mayo Clin Proc (1992) 1.04
Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer (1985) 1.04
Fournier's gangrene complicating aggressive therapy for hematologic malignancy. Cancer (1986) 1.03
Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma. J Clin Oncol (1995) 1.03
Diagnostic concurrence in the subclassification of adult acute leukemia using French-American-British criteria. Cancer (1982) 1.02
Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol (1999) 1.02
Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. Br J Haematol (1998) 1.02
Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood (1988) 1.01
Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant (2010) 1.01
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant (2003) 1.01
High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med (1986) 1.00
Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol (1984) 1.00
Feasibility of semen cryopreservation in patients with malignant disease. JAMA (1980) 0.99
A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood (2000) 0.99
Hypoplastic acute leukemia. Cancer (1981) 0.98
Thrombotic complications of silicone rubber catheters during autologous marrow and peripheral stem cell transplantation: prospective comparison of Hickman and Groshong catheters. Bone Marrow Transplant (1991) 0.98
Lymphoma classification--the gap between biology and clinical management is closing. Blood (1996) 0.98
SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. Bone Marrow Transplant (2010) 0.97
Antitumour effect of cimetidine. Lancet (1979) 0.97
The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Ann Oncol (2009) 0.97
Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood (1995) 0.97
Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant (2006) 0.96